Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
NCT04448522
Reduced vs Conventional Dosage Intensity-modulated Radiotherapy for Chemotherapy-sensitive Stage II-III Nasopharyngeal Carcinoma
- NCT04448522 ↗
- Recruiting
- Sun Yat-sen University
- Focused
We haven't built an HCP commentary report on NCT04448522 (chemotherapy-sensitive stage II-III nasopharyngeal carcinoma; tests no drug) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT04448522 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 5 |
The trial
ClinicalTrials.gov- Official title
- A Multicenter Randomized Controlled Trial Comparing Reduced Dose With Regular Dose Intensity-modulated Radiotherapy for Chemotherapy Sensitive Stage II-III Nasopharyngeal Carcinoma
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Nasopharyngeal Carcinoma; Radiotherapy; Chemotherapy
- Interventions
- reduced dosage IMRT; conventional dosage IMRT
- Arms
- Reduced dosage IMRT group · Experimental
- Conventional dosage IMRT group · Active comparator
- Enrollment
- 508 (estimated)
- Primary outcomes
- Progress-free survival (PFS)
- Sponsor
- Sun Yat-sen University with National Cancer Centre, Singapore, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Zhongshan People's Hospital, Guangdong, China, Yuebei People's Hospital, Wuzhou Red Cross Hospital
- Start
- Aug 18, 2020
- Primary completion
- Aug 2026 (estimated)
- Results posted
- No
- Registry record
- NCT04448522 · updated Sep 28, 2020